No connection

Search Results

ABCL vs KMTS

ABCL
AbCellera Biologics Inc.
NEUTRAL
Price
$3.49
Market Cap
$1.06B
Sector
Healthcare
AI Confidence
72%
KMTS
Kestra Medical Technologies, Ltd.
BEARISH
Price
$17.87
Market Cap
$1.04B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ABCL
--
KMTS
--
Forward P/E
ABCL
-4.53
KMTS
-8.35
P/B Ratio
ABCL
1.08
KMTS
3.62
P/S Ratio
ABCL
14.08
KMTS
12.46
EV/EBITDA
ABCL
-3.42
KMTS
-5.9

Profitability

Gross Margin
ABCL
-148.68%
KMTS
48.75%
Operating Margin
ABCL
-63.72%
KMTS
-141.6%
Profit Margin
ABCL
-194.88%
KMTS
-172.99%
ROE
ABCL
-14.47%
KMTS
-92.65%
ROA
ABCL
-9.99%
KMTS
-36.84%

Growth

Revenue Growth
ABCL
788.2%
KMTS
62.7%
Earnings Growth
ABCL
--
KMTS
--

Financial Health

Debt/Equity
ABCL
0.15
KMTS
0.16
Current Ratio
ABCL
11.32
KMTS
7.32
Quick Ratio
ABCL
10.07
KMTS
7.08

Dividends

Dividend Yield
ABCL
--
KMTS
--
Payout Ratio
ABCL
0.0%
KMTS
0.0%

AI Verdict

ABCL NEUTRAL

ABCL exhibits severe financial distress according to the Piotroski F-Score (1/9), indicating weak operational and financial health. The Altman Z-Score is unavailable, but the company's negative profitability metrics—particularly a -194.88% profit margin and -14.47% ROE—highlight deep operational inefficiencies. Despite a 788.2% YoY revenue growth and strong earnings surprise history (average +30.86% over last 4 quarters), the company remains unprofitable and carries significant valuation risk. The current price of $3.49 trades at a steep 14.08 Price/Sales ratio, far exceeding sector averages, suggesting speculative pricing. Analysts' target price of $9.17 implies strong upside potential, but this is based on unproven profitability and high risk.

Strengths
Exceptional 788.2% YoY revenue growth, signaling strong market traction
Positive earnings surprise history (average +30.86% over last 4 quarters)
Strong recent Q/Q EPS growth (+84.2%) and year-over-year EPS improvement (+75.0%)
Risks
Piotroski F-Score of 1/9 indicates severe financial and operational weakness
Negative profit, operating, and gross margins across all metrics (-194.88%, -63.72%, -148.68%)
No Graham Number or intrinsic value estimate due to lack of profitability and negative earnings
KMTS BEARISH

KMTS exhibits severe fundamental weakness, highlighted by a critical Piotroski F-Score of 1/9, indicating poor operational health and financial instability. Despite strong top-line revenue growth of 62.7% and a high current ratio of 7.32, the company suffers from deep negative profit margins (-172.99%) and a complete lack of positive earnings. The disconnect between the 'Strong Buy' analyst consensus and the actual technical trend (0/100) and bearish insider selling suggests a significant valuation bubble or over-optimism regarding future scaling.

Strengths
Strong YoY revenue growth of 62.70%
Excellent short-term liquidity (Current Ratio 7.32)
Healthy Gross Margin of 48.75% suggesting product viability
Risks
Critical operational failure indicated by Piotroski F-Score of 1/9
Severe negative profitability (Profit Margin -172.99%)
Strong bearish technical trend with consistent price declines

Compare Another Pair

ABCL vs KMTS: Head-to-Head Comparison

This page compares AbCellera Biologics Inc. (ABCL) and Kestra Medical Technologies, Ltd. (KMTS) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile